Page last updated: 2024-10-22

ambroxol and Cacosmia

ambroxol has been researched along with Cacosmia in 1 studies

Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
O'Byrne, L1
Webster, KE1
MacKeith, S1
Philpott, C1
Hopkins, C1
Burton, MJ1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Smell in Covid-19 and Efficacy of Nasal Theophylline[NCT04789499]Phase 251 participants (Actual)Interventional2021-03-15Completed
Efficacy and Safety of Phototherapy in the Treatment of Loss of Smell Post Acute Infection of Coronavirus 19[NCT05177445]40 participants (Anticipated)Interventional2022-04-30Not yet recruiting
Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study[NCT04342728]214 participants (Actual)Interventional2020-04-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

36-Item Short Form Health Survey (SF-36)

The SF-36 is a well-established 36-item questionnaire evaluating physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. This test allows us to study the overall quality of life for those suffering from COVID-19 related OD. There is no single overall score for SF-36. The SF 36 generates 8 subscales with scores ranging from 0 (worst) to 100 (best). General health domain scores are reported here. (NCT04789499)
Timeframe: Baseline assessment

Interventionscore on a scale (Median)
Theophylline75
Placebo80

Change in Questionnaire for Olfactory Dysfunction (QOD) From Baseline to 6 Weeks Post Intervention

Questionnaire for Olfactory Dysfunction (QOD) assesses health-related quality of life of participants based on four factors such as eating, mental health, social interactions, or fear of dysfunction.. The survey also includes questions on parosmia, a phenomena of COVID-related OD. The QOD consists of 17 statements that participants score from 0-3, resulting in a total score from 0 to 51. Higher scores reflect better olfactory-specific QOL. (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline

Interventionscore on a scale (Median)
Theophylline0.86
Placebo1.43

Olfactory Dysfunction Outcomes Rating (ODOR)

The ODOR is a 28-item QOL instrument with a total score ranging from 0 to 112 points. Higher scores indicate worse QOL with higher degree of dysfunction and limitation. A decrease of 15 or more points is deemed to be a clinically significant improvement in QOL. (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups

Interventionscore on a scale (Median)
Theophylline-6.5
Placebo-4.5

University of Pennsylvania Smell Identification Test (UPSIT)

"UPSIT 0-40 with higher scores indicating better smell.~This test is an objective, clinically validated 40-question forced-choice odor identification test where microencapsulated odorants on a strip are released by scratching. Out of a total of 40 points, normosmia is defined as ≥34 for males and ≥35 for females, and an increase in ≥4 points will be deemed a clinically significant improvement in symptoms." (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline

Interventionscore on a scale (Median)
Theophylline3
Placebo0

UPSIT

"UPSIT 0-40 with higher scores indicating better results.~The response rate defined as the number of participants in each group self-reporting of at least slightly better improvement in the Clinical Global Improvement Scale at 6 weeks post intervention as compared to baseline, devided by the total number of participants in that specific group. The CGI-Improvement Scale has seven response options (from 1 as Very Much Improved to 7 as Very Much Worsened) for answers to the question Compared to your sense of smell before you started the nasal irrigations, how would you rate your sense of smell now . Participants reporting 3 as Minimally Improved, 2 as Much Improved, or 1 as Very Much Improved in the CGI-I will be deemed responders to treatment, and the rate of responders will be compared between the two arms." (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups

Interventionpercentage of participants (Number)
Theophylline59
Placebo43

Reviews

1 review available for ambroxol and Cacosmia

ArticleYear
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    The Cochrane database of systematic reviews, 2021, 07-22, Volume: 7

    Topics: Administration, Oral; Ambroxol; Betamethasone; Bias; COVID-19; Expectorants; Glucocorticoids; Humans

2021